AHD International, Importer and Distributor of Nutraceutical Ingredients
Products

Anti-Oxidants & Immune Enhancing Ingredients

Cardiovascular Health

Ingredients for Healthy Joints and Cartilage

Memory & Mental Enhancing Ingredients

Menopause and Women's Health

Mood and Emotional Health

Weight Loss

All Natural Products

Product Infomation

Nutraceutical News
Clinical Studies

Resources

Links
Resources

What's Hot?
Collagen Bulk Sales
Hoodia Bulk Sales
Hyaluronic Acid
Who We Are
About AHD
Contact AHD

Collagen Clinical Study


Collagen-Induced Arthritis in Mice: A Major Role for Tumor Necrosis Factor-alpha.

Williams RO.

Collagen-induced arthritis is the most widely used animal model for the evaluation of novel therapeutic strategies for rheumatoid arthritis. The disease is induced by immunization of genetically susceptible strains of mice or rats with type II collagen in adjuvant. Susceptibility to collagen-induced arthritis is associated with major histocompatibility complex (MHC) class II genes, although non-MHC genes also play a role. Both B- and T-lymphocytes are important in the pathogenesis of collagen-induced arthritis, with the peak of the T-cell response occurring around the time of disease onset. Histopathological assessment of the joints of animals with collagen-induced arthritis reveal a proliferative synovitis with infiltration of polymorphonuclear and mononuclear cells, the formation of an erosive pannus, cartilage degradation, and fibrosis. As in human rheumatoid arthritis, a number of both pro- and anti-inflammatory cytokines are expressed in the joints of mice with collagen-induced arthritis, including tumor necrosis factor-alpha (TNFalpha) and interleukin (IL)-1beta, IL-6, IL-1Ra, IL-10, and transforming growth factor beta. The use transgenic and knockout strains of mice, as well as biological inhibitors, have revealed important pathological roles for multiple cytokines. Of these, TNFalpha emerged as a valid therapeutic target for rheumatoid arthritis and this led to the setting up of clinical trials of anti-TNFalpha antibody therapy. Three anti-TNFalpha biologics(infliximab, etanercept, and adalimumab) are now approved for use and TNFalpha blockade therefore represents an important advance in our ability to treat rheumatoid arthritis.

PMID: 17172717 [PubMed - in process]


<< Back to Collagen Clinical Study List



We are strictly a bulk supplier to manufacturers – we do not sell to re-sellers or individuals. Our minimum order size is approximately 25 kilos. We are one of only a few suppliers that carry $5 million product liability insurance for our customers. AHD International LLC is classified as a importer, exporter, manufacturer, distributor of nutritional ingredients depending on the ingredient specified. AHD has 5 warehouse locations across North America and sales agents in over 10 countries. We are the only ingredient company to be awarded the Dun and Bradstreet's fastest growing company in America twice in 1999 and 2002.

For quotes please click here

*"These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."



© AHD International, LLC.
Legal and Privacy Statement

Entrepeneur Hot 100

Named in Dun & Bradstreet Entrepreneur Magazine "Hot 100" fastest growing companies.
For Vendors

Get a Quote
Partner With Us

Choose AHD

AHD has over 650 customers.

5 North American warehouses making large quantity orders and quick delivery possible.

Representatives in USA, Mexico, Chile, Brazil and Uruguay.

AHD has a reputation for carrying the highest quality products in the industry.

Exclusivity of premium products from some of the top nutraceutical companies world. wide.

News

Industry News
Business News
Food & Beverage
Sports Nurtition